Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indene SCHEMBL29492590 | 1.00 | CA1 (0.53) | CA1CA2CYP2D6CYP2C19PARP1 | |
| Indene SCHEMBL27842909 | 1.00 | CA1 (0.53) | CA1CA2CYP2D6CYP2C19PARP1 | |
| Indene SCHEMBL27564191 | 0.97 | CA1 (0.52) | CA1CA2CYP2D6CYP2C19PARP1 | |
| Indene SCHEMBL8336138 | 0.97 | CA1 (0.55) | CA1CA2CYP2D6CYP2C19PARP1 | |
| Indene SCHEMBL8617 | 0.97 | — | — | |
| Indene SCHEMBL29350094 | 0.97 | — | — | |
| Indene SCHEMBL23071394 | 0.95 | CA1 (0.53) | CA1CA2CYP2D6CYP2C19PARP1 | |
| Indene SCHEMBL1054910 | 0.95 | CA1 (0.53) | CA1CA2CYP2D6CYP2C19PARP1 | |
| Indene SCHEMBL8971559 | 0.95 | CA1 (0.53) | CA1CA2CYP2D6CYP2C19PARP1 | |
| Indene SCHEMBL7153004 | 0.95 | CA1 (0.53) | CA1CA2CYP2D6CYP2C19PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079791-A | Racemization method of chiral indene amine | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079792-A | Synthesis method of chiral indene amine | — | 2026-05-26 | — | — | CN | claimed |
| CN-119798092-A | Imine intermediate of indenofloxacin, cis-indene intermediate and preparation method thereof | 宁夏格瑞精细化工有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119661374-A | Method for preparing (1R, 2S) -2, 6-dimethyl-1-indene amine by using chiral amino acid resolving agent | 中国科学院大连化学物理研究所 | 2025-03-21 | — | — | CN | claimed |
| CN-119462395-A | Synthesis method of chiral indene amine | 中国科学院大连化学物理研究所 | 2025-02-18 | — | — | CN | claimed |
| CN-118878424-A | Synthesis method of indene fluorooxamide intermediate indene amine | 安徽省化工研究院 | 2024-11-01 | — | — | CN | claimed |
| EP-3429352-B1 | PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM | FMC CORP (US) | 2021-05-05 | — | — | EP | claimed |
| CN-108777958-B | Process for converting the S-enantiomer into its racemic form | FMC有限公司 | 2021-03-12 | — | — | CN | claimed |
| US-10570086-B2 | Process for converting S-enantiomer to its racemic form | FMC CORPORATION (US) | 2020-02-25 | — | — | US | claimed |
| EP-3560911-A1 | PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM | FMC Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| CN-108586455-A | A kind of preparation method of 8- alkenyls Indoli zine derivatives | 淮阴师范学院 | 2018-09-28 | — | — | CN | claimed |
| CN-106478429-B | A kind of method of the trans indenes amine alcohol of synthesis of chiral | 上海瀚鸿科技股份有限公司 | 2018-02-13 | — | — | CN | claimed |
| WO-2017160933-A1 | PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM | FMC CORPORATION (US) | 2017-09-21 | — | — | WO | claimed |
| CN-106480119-A | A kind of preparation method of chirality indenes amine | 陈永军 | 2017-03-08 | — | — | CN | claimed |
| CN-103113306-A | Synthesis method of 2,3-benzopyrrole compound NPS-1577 | UNIV TONGJI | 2013-05-22 | — | — | CN | claimed |
| CN-100473654-C | S-type 4-substituted hydroxypyranoindolidine compound and its derivative and preparation method thereof | TANABE SEIYAKU CO (JP) | 2009-04-01 | — | — | CN | claimed |
| CN-100429203-C | Dyeing compsn. for kerationous fibres comprising particular dicationic diazo dye | OREAL (FR) | 2008-10-29 | — | — | CN | claimed |
| CN-1294123-C | Composition for dyeing keratinous fibres comprising a particular dicationic diazo dye | OREAL (FR) | 2007-01-10 | — | — | CN | claimed |
| CN-1551756-A | Composition for dyeing keratinous fibres comprising a particular dicationic diazo dye | �ź㴫 | 2004-12-01 | — | — | CN | claimed |
| CN-1541207-A | Dyeing compsn. for kerationous fibres comprising particular dicationic diazo dye | �ź㴫 | 2004-10-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570086-B2 | Process for converting S-enantiomer to its racemic form | ADRM1, SULT1E1, CYP3A4 | CA1 4473/4885CA2 4103/4885CYP2D6 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.